Mansfield, J C, Parkes, M, Hawthorne, A B, Forbes, A ORCID: https://orcid.org/0000-0001-7416-9843, Probert, C S J, Perowne, R C, Cooper, A, Zeldis, J B, Manning, D C and Hawkey, C J
(2007)
A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease.
Alimentary Pharmacology and Therapeutics, 26 (3).
pp. 421-430.
ISSN 0269-2813
Abstract
Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | adolescent,adult,aged,crohn disease,double-blind method,female,humans,immunosuppressive agents,male,middle aged,placebos,severity of illness index,thalidomide,treatment outcome,venous thrombosis |
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine |
Depositing User: | Pure Connector |
Date Deposited: | 06 Aug 2014 10:50 |
Last Modified: | 21 Oct 2022 00:01 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/49680 |
DOI: | 10.1111/j.1365-2036.2007.03385.x |
Actions (login required)
![]() |
View Item |